Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0WOBTH
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
DS-3939
|
|||||
| Synonyms |
DS-3939; GT-00A ADC; DS-3939a
Click to Show/Hide
|
|||||
| Organization |
Daiichi Sankyo (Originator)
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Drug-to-Antibody Ratio |
7.9
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Gatipotuzumab
|
Antibody Info | ||||
| Antigen Name |
Mucin-1 (MUC1)
|
Antigen Info | ||||
| Payload Name |
DXd
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mc-Gly-Gly-Phe-Gly
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
deruxtecan
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients (ECOG 0-1, LVEF ≥50%, measurable disease) must provide tumor samples for MUC1 analysis; exclusions include prior MUC1 therapy, active CNS metastases, uncontrolled infections (HIV/HBV/HCV), interstitial lung disease, or thromboembolic/autoimmune disorders within 6 months.
|
||||
| Administration Dosage |
One IV infusion Q3W on Day 1 of each 21-day cycle.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05875168 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description | Phase 1/2, Open-label, Multicenter, First-in-Human Study of DS-3939a in Subjects With Advanced Solid Tumors | ||||
| Primary Endpoint |
The study assesses dose-limiting toxicities (DLTs) within 3 months and tracks treatment-emergent adverse events (AEs) with objective response rates over ~31 months.
|
||||
| Other Endpoint |
Efficacy is evaluated via objective response rate, disease control rate, duration of response, and survival outcomes (PFS, OS) over ~31 months, alongside pharmacokinetic (AUC, Cmax, Tmax, T1/2) and immunogenicity (anti-drug antibodies) profiling extending up to 47 months, with TA-MUC1 expression analyzed at baseline.
|
||||